期刊
EUROPEAN HEART JOURNAL
卷 36, 期 30, 页码 1983-1989出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv242
关键词
Cardiac resynchronization therapy; Narrow QRS; QRS duration
资金
- Amgen
- Astra-Zeneca
- Bayer
- Biotronik
- Biosense Webster
- Boehringer-Ingelheim
- Boston Scientific
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Cook Medical
- Medtronic
- Novartis
- Pfizer
- Roche
- Sanofi-Aventis
- Sorin
- St. Jude Medical
- Bayer Healthcare
- Sorin Group
- CardioInsight
- Respicardia Inc.
- GE Healthcare
- Lantheus
- Servier
- Edwards Lifesciences
- Cardiorentis
- ARMGO
- Celladon
- RESMED
- GE
- EBR systems
Aims In EchoCRT, a randomized trial evaluating the effect of cardiac resynchronization therapy (CRT) in patients with a QRS duration of <130 ms and echocardiographic evidence of left ventricular dyssynchrony, the primary outcome occurred more frequently in the CRT when compared with the control group. According to current heart failure guidelines, CRT is recommended in patients with a QRS duration of >= 120 ms. However, there is some ambiguity from clinical trial data regarding the benefit of patients with a QRS duration of 120-130 ms. Methods and results The main EchoCRT trial was prematurely terminated due to futility. For the current subgroup analysis we compared data for CRT-ON vs. -OFF in patients with QRS < 120 (n = 661) and QRS 120-130 ms (n = 139). On uni- and multivariable analyses, no significant interaction was observed between the two groups and randomized treatment for the primary or any of the secondary endpoints. On multivariable analysis, a higher risk for the primary endpoint was observed in patients with a QRS duration of 120-130 ms randomized to CRT-ON vs. CRT-OFF (hazard ratio 2.18, 95% CI 1.02-4.65; P = 0.044). However, no statistically significant interaction, compared with patients with QRS < 120 ms randomized to CRT-ON vs. CRT-OFF, was noted (P-interaction = 0.160). Conclusions In this pre-specified subgroup analysis of EchoCRT, no benefit of CRT was evident in patients with a QRS duration of 120-130 ms. These data further question the usefulness of CRT in this patient population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据